Advertisement
PRQR vs VIR
Which Stock Would AI Choose? ProQR Therapeutics (PRQR) vs. Vir Biotechnology (VIR) Stock Comparison
Key Takeaways
- PRQR (ProQR Therapeutics) is a clinical-stage RNA-editing biotech with a modest revenue base and a narrower cash runway, while VIR (Vir Biotechnology) holds a substantially larger cash position after recent financings and partnerships.
- Both companies are pre-profitability and heavily dependent on clinical catalysts, making their relative performance driven by trial data and partnership news rather than fundamentals.
- VIR has shown stronger recent share-price momentum, supported by a large Astellas oncology collaboration and advancing late-stage hepatitis delta programs.
- PRQR trades near multi-year lows with a wide gap between its current price and consensus analyst targets, reflecting both upside potential and execution risk.
- The two stocks carry different sector exposures and risk profiles: VIR spans oncology and infectious disease, while PRQR focuses on genetic-disease RNA therapies.
- For more detail on each company's latest developments and intraday action, explore the PRQR Major News and PRQR Today's Price Move pages, as well as the VIR Major News and VIR Today's Price Move pages.
- To see how AI-driven strategies are navigating this environment, explore Trending AI Robots.
Introduction
Investors evaluating speculative biotechnology names often weigh scientific promise against financial durability, and the comparison between PRQR and VIR captures that tension precisely. ProQR Therapeutics is a Netherlands-based developer of RNA-editing medicines for rare genetic diseases, while Vir Biotechnology is an infectious-disease and oncology company transitioning toward T-cell engager (TCE) therapies for solid tumors. Both stocks appeal to growth-oriented traders and long-horizon investors who can tolerate binary clinical risk. This stock comparison examines their recent performance, market positioning, and relative momentum to clarify where each company stands in the current market environment.
PRQR Overview and Recent Performance
ProQR Therapeutics (PRQR) is a clinical-stage biotechnology company built around its Axiomer RNA-editing platform, which uses a cell's own ADAR editing machinery to make precise single-nucleotide changes in RNA. The company's pipeline includes AX-0811 for cholestatic liver disease, which recently dosed its first participant in a Phase 1 trial, along with earlier-stage programs targeting Hurler syndrome and MASH (metabolic dysfunction-associated steatohepatitis).
In recent weeks, sentiment has been shaped by a mix of clinical progress and valuation concerns. The company reported higher revenue alongside a narrowed loss in its most recent quarter, and it has strengthened its platform focus through an AI advisory board with Ginkgo Bioworks and a collaboration with Eli Lilly. Despite these steps, the shares have traded at relatively low levels, and at least one analyst lowered its price target while maintaining a Buy rating, citing execution and regulatory-path uncertainty. The company's modest cash balance, projected to fund operations into mid-2027, remains a key factor in how investors assess its market positioning.
VIR Overview and Recent Performance
Vir Biotechnology (VIR) is an immunology company advancing a PRO-XTEN platform of dual-masked T-cell engagers across oncology, alongside a hepatitis delta program built on tobevibart and elebsiran. Its lead oncology candidate, VIR-5500, targets PSMA (prostate-specific membrane antigen) in prostate cancer and is the subject of a global collaboration with Astellas valued at up to $1.7 billion. The company has also signed a collaboration with Gilead focused on additional T-cell engager candidates.
Recent market activity has reflected a balance between clinical momentum and ongoing losses. Positive updated Phase 1 data for VIR-5500 and encouraging long-term Phase 2 hepatitis delta results have supported the shares, which have posted notable gains over the trailing year. At the same time, the company reported a wider quarterly net loss and completed a follow-on equity offering. With cash and investments of roughly $809 million expected to fund operations into the second half of 2028, VIR carries a comparatively long runway for a development-stage biotech.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI trading bots chosen for their suitability to current market conditions. While Tickeron offers hundreds of AI trading bots that collectively trade thousands of different tickers, only the strongest performers earn a place in this featured section. These bots operate with distinct trading styles, strategies, timeframes, performance statistics, and sets of tickers they monitor, giving traders a range of approaches to evaluate. The platform presents measurable metrics that allow users to compare bot performance and identify strategies aligned with their own objectives. For investors following names such as PRQR and VIR, reviewing the Trending AI Robots can provide an additional, data-driven perspective on current market positioning.
Head-to-Head Comparison
The clearest contrast between these two companies lies in scale and diversification. VIR operates across two therapeutic areas with multiple clinical-stage assets and has secured large, validating partnerships that extend its cash runway into 2028. PRQR is more narrowly focused on a single platform and earlier-stage pipeline, with a smaller balance sheet and a funding horizon into mid-2027. In terms of growth drivers, VIR benefits from near-term data readouts and late-stage trials, while PRQR's catalysts are weighted toward earlier clinical milestones.
Risk factors also differ. PRQR faces concentrated execution risk tied to a limited number of programs and potential future dilution. VIR carries binary trial risk across both oncology and hepatitis delta, though its larger cash cushion provides a degree of buffer. On market sentiment, VIR's recent share-price momentum has been stronger, whereas PRQR trades at a wide discount to consensus targets, reflecting skepticism about its regulatory path. Both remain speculative equities whose relative performance will hinge on clinical data rather than near-term earnings.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor VIR in the current environment. The stock demonstrates stronger and more consistent recent trend momentum, a substantially larger cash runway, and a more diversified pipeline with nearer-term catalysts across oncology and hepatitis delta. By contrast, PRQR presents a higher degree of concentration and financing risk, even as its depressed valuation implies greater potential upside if its clinical programs succeed. This assessment is probabilistic rather than definitive, and relative positioning could shift quickly on trial results or partnership developments.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PRQR is a Hold and VIR is a Hold.
Momentum Indicator for PRQR turns positive, indicating new upward trend
PRQR saw its Momentum Indicator move above the 0 level on November 04, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 97 similar instances where the indicator turned positive. In 83 of the 97 cases, the stock moved higher in the following days. The odds of a move higher are at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where PRQR's RSI Oscillator exited the oversold zone, 24 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for PRQR just turned positive on October 28, 2026. Looking at past instances where PRQR's MACD turned positive, the stock continued to rise in 37 of 44 cases over the following month. The odds of a continued upward trend are 84%.
Following a +6.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRQR advanced for three days, in 173 of 210 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
PRQR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 49 of 59 cases where PRQR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRQR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for PRQR entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 24 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 39 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.504) is normal, around the industry mean (2.904). P/E Ratio (-3.525) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (9.294) is also within normal values, averaging (440.869).
The Tickeron Seasonality Score of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. PRQR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRQR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
VIR saw its Stochastic Oscillator peaks and leaves the overbought zone
The Stochastic Oscillator for VIR moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 51 similar instances where the indicator exited the overbought zone. In 42 of the 51 cases the stock moved lower. This puts the odds of a downward move at 82%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VIR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on VIR as a result. In 77 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for VIR just turned positive on October 27, 2026. Looking at past instances where VIR's MACD turned positive, the stock continued to rise in 33 of 41 cases over the following month. The odds of a continued upward trend are 80%.
VIR moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for VIR crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 76%.
Following a +7.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where VIR advanced for three days, in 205 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
VIR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 125 of 159 cases where VIR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.027) is normal, around the industry mean (2.904). P/E Ratio (-6.650) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (5.168) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. VIR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 79 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VIR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
PRQR | VIR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 6 | 6 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 39 Fair valued | 20 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 96 | |
PRICE GROWTH RATING 1..100 | 78 | 37 | |
P/E GROWTH RATING 1..100 | 24 | 79 | |
SEASONALITY SCORE 1..100 | 42 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
VIR's Valuation (20) in the null industry is in the same range as PRQR (39) in the Biotechnology industry. This means that VIR’s stock grew similarly to PRQR’s over the last 12 months.
VIR's Profit vs Risk Rating (100) in the null industry is in the same range as PRQR (100) in the Biotechnology industry. This means that VIR’s stock grew similarly to PRQR’s over the last 12 months.
VIR's SMR Rating (96) in the null industry is in the same range as PRQR (98) in the Biotechnology industry. This means that VIR’s stock grew similarly to PRQR’s over the last 12 months.
VIR's Price Growth Rating (37) in the null industry is somewhat better than the same rating for PRQR (78) in the Biotechnology industry. This means that VIR’s stock grew somewhat faster than PRQR’s over the last 12 months.
PRQR's P/E Growth Rating (24) in the Biotechnology industry is somewhat better than the same rating for VIR (79) in the null industry. This means that PRQR’s stock grew somewhat faster than VIR’s over the last 12 months.
| PRQR | VIR | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 83% | N/A |
| Stochastic ODDS (%) | 1 day ago 83% | 1 day ago 82% |
| Momentum ODDS (%) | 1 day ago 86% | 1 day ago 84% |
| MACD ODDS (%) | 1 day ago 84% | 1 day ago 80% |
| TrendWeek ODDS (%) | 1 day ago 82% | 1 day ago 81% |
| TrendMonth ODDS (%) | 1 day ago 84% | 1 day ago 78% |
| Advances ODDS (%) | 1 day ago 82% | 1 day ago 76% |
| Declines ODDS (%) | 3 days ago 84% | 3 days ago 81% |
| BollingerBands ODDS (%) | 1 day ago 77% | 1 day ago 76% |
| Aroon ODDS (%) | 1 day ago 83% | 1 day ago 79% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
PRQR’s FA Score shows that 1 FA rating(s) are green while VIR’s FA Score has 1 green FA rating(s).
- PRQR’s FA Score: 1 green, 4 red.
- VIR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
PRQR’s TA Score shows that 5 TA indicator(s) are bullish while VIR’s TA Score has 7 bullish TA indicator(s).
- PRQR’s TA Score: 5 bullish, 3 bearish.
- VIR’s TA Score: 7 bullish, 2 bearish.
Price Growth
PRQR (@Biotechnology) experienced а 0.00% price change this week, while VIR (@Biotechnology) price change was -1.34% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -3.38%. For the same industry, the average monthly price growth was -11.00%, and the average quarterly price growth was -16.20%.
Reported Earning Dates
PRQR is expected to report earnings on Nov 05, 2026.
VIR is expected to report earnings on Feb 25, 2027.
Industries' Descriptions
@Biotechnology (-3.38% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
VIR and
Correlation & Price change
A.I.dvisor indicates that over the last year, VIR has been loosely correlated with BEAM. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if VIR jumps, then BEAM could also see price increases.
| Ticker / NAME | Correlation To VIR | 1D Price Change % | ||
|---|---|---|---|---|
| VIR | 100% | +4.90% | ||
| BEAM - VIR | 55% Loosely correlated | +5.55% | ||
| EDIT - VIR | 54% Loosely correlated | +4.62% | ||
| DNLI - VIR | 53% Loosely correlated | +7.76% | ||
| PRME - VIR | 53% Loosely correlated | +9.23% | ||
| RCUS - VIR | 51% Loosely correlated | +2.12% | ||
More | ||||